Biovail launches bedtime blood pressure treatment

Tiazac XC is a novel, extended-release formulation of diltiazem hydrochloride that features a new diffusion technology (DiTech) delivery system designed for night-time administration, resulting in improved 24-hour blood pressure (BP) control with additional BP control during the early morning hours.

The improved release technology in Tiazac XC allows for bedtime administration, thereby targeting the high-risk morning surge in blood pressure that most patients experience. Importantly, bedtime dosing may mitigate some common side effects of diltiazem treatment, as suggested by the fact that the incidence of edema was not statistically different with Tiazac XC, compared with placebo.

Building on the success of Biovail’s Tiazac, Canada’s leading once-daily diltiazem formulation, Biovail’s Canadian sales team is now fully ready to market the new product to physicians and pharmacists. In addition to physician calls to introduce Tiazac XC, launch elements include sampling, marketing and other promotional activities.

Tiazac XC is indicated for the treatment of high blood pressure (hypertension). The treatment works by slowing the heart rate, and by relaxing and widening arteries, which reduces blood pressure. Widening of the coronary arteries also increases the amount of blood reaching the heart.

Tiazac XC belongs to a class of anti-hypertensive drugs known as non-dihydropyridine calcium channel blockers (CCBs).